Cargando…
Efficacy and safety of botulinum toxin type A for treatment of Frey’s syndrome: evidence from 22 published articles
Frey’s syndrome (FS) is an unavoidable sequela following the surgery of the parotid gland. Although several treatment methods are available, their efficacy is short term or accompanied by unacceptable complications. In the past two decades, botulinum toxin type A (BTXA) has been widely used to treat...
Autores principales: | Xie, Shang, Wang, Kan, Xu, Tao, Guo, Xue-Sheng, Shan, Xiao-Feng, Cai, Zhi-Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673990/ https://www.ncbi.nlm.nih.gov/pubmed/26310612 http://dx.doi.org/10.1002/cam4.504 |
Ejemplares similares
-
Use of botulinum toxin in Frey's syndrome
por: Freni, Francesco, et al.
Publicado: (2019) -
Use of botulinum toxin type A in Frey's syndrome
por: Gualberto, Gustavo Vieira, et al.
Publicado: (2017) -
The incidence of Frey syndrome and treatment with botulinum toxin in the Central Denmark Region
por: Golding, Christian N., et al.
Publicado: (2022) -
Management of parotid fistula and Frey's syndrome with Botulinum neurotoxin type A
por: Chowdhury, Ripon, et al.
Publicado: (2021) -
Botulinum toxin type A interrupts autophagic flux of submandibular gland
por: Xie, Shang, et al.
Publicado: (2019)